Cargando…

Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis

BACKGROUND: Linezolid has shown strong antimicrobial activity against multidrug-resistant (MDR)/rifampin-resistant strains of Mycobacterium tuberculosis. Linezolid achieves clinical efficacy mainly through area under the concentration time curve/minimum inhibitory concentration ratio in the infected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuan, Huang, Hairong, Dong, Weijie, Lan, Tinglong, Fan, Jun, Wen, Shu’an, Zhang, Tingting, Qin, Shibing, Guo, Ai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776296/ https://www.ncbi.nlm.nih.gov/pubmed/31581274 http://dx.doi.org/10.1371/journal.pone.0223391

Ejemplares similares

Application of three-dimensional printing technology for spinal tuberculosis
por: Wang, Heng, et al.
Publicado: (2022)

Diagnostic accuracy evaluation of the conventional and molecular tests for Spinal Tuberculosis in a cohort, head-to-head study
por: Wang, Guirong, et al.
Publicado: (2018)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

The Comparative Influence of 2 and 4 Weeks Preoperative Antituberculosis Treatment on Spinal Tuberculosis Surgery: A Multicenter, Prospective, Randomized Clinical Trial
por: Fan, Jun, et al.
Publicado: (2021)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
por: Yuan, Yuan, et al.
Publicado: (2022)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Cerebrospinal fluid penetration of linezolid in neurosurgical patients
por: Myrianthefs, P, et al.
Publicado: (2006)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
por: Azimi, Taher, et al.
Publicado: (2022)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018
por: McDowell, Ashley, et al.
Publicado: (2020)

Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report
por: Lee, Jaemin, et al.
Publicado: (2021)

Intrathecal/Intraventricular Linezolid in Multidrug-Resistant Enterococcus faecalis Ventriculitis
por: Lich, Brian F., et al.
Publicado: (2016)

Linezolid for drug‐resistant pulmonary tuberculosis
por: Singh, Bhagteshwar, et al.
Publicado: (2019)

In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China
por: Yu, Xia, et al.
Publicado: (2021)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria
por: Oehadian, Amaylia, et al.
Publicado: (2022)

Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature
por: Swaminathan, Aravind, et al.
Publicado: (2017)

Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme?
por: Bharadwaj, Renu
Publicado: (2021)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
por: Deshpande, Devyani, et al.
Publicado: (2016)

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies
por: Garcia-Prats, Anthony J., et al.
Publicado: (2019)

Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India
por: Tornheim, J.A., et al.
Publicado: (2020)

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
por: Oehadian, Amaylia, et al.
Publicado: (2022)

Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis
por: Zhang, Tingting, et al.
Publicado: (2019)

Linezolid for Treating Tuberculosis: A Delicate Balancing Act
por: Maartens, Gary, et al.
Publicado: (2015)

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
por: Deshpande, Devyani, et al.
Publicado: (2016)

Linezolid- and Multidrug-Resistant Enterococci in Raw Commercial Dog Food, Europe, 2019–2020
por: Freitas, Ana R., et al.
Publicado: (2021)

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis
por: Agyeman, Akosua Adom, et al.
Publicado: (2016)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy
por: Brown, Ashley N., et al.
Publicado: (2015)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Transregional movement of multidrug-resistant tuberculosis in north China: an underlying threat to tuberculosis control
por: An, Jun, et al.
Publicado: (2016)

Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China
por: Fang, Mu-Tong, et al.
Publicado: (2021)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

Changes in chest CT findings of pulmonary tuberculosis after linezolid treatment
por: Kim, Sanghyeon, et al.
Publicado: (2013)

Graphene Oxide-Linezolid Combination as Potential New Anti-Tuberculosis Treatment
por: De Maio, Flavio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lndc38kppb5cbqv1o3bimmq7qm